Resveratrol

Generic Name
Resveratrol
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C14H12O3
CAS Number
501-36-0
Unique Ingredient Identifier
Q369O8926L
Background

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of...

Indication

Being investigated for the treatment of Herpes labialis infections (cold sores).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Resveratrol for Pain Due to Endometriosis

Phase 4
Completed
Conditions
Endometriosis
Interventions
Drug: Placebo
Drug: Resveratrol
First Posted Date
2015-06-18
Last Posted Date
2016-10-14
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
44
Registration Number
NCT02475564
Locations
🇧🇷

HCPA, Porto Alegre, RS, Brazil

Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood

Not Applicable
Conditions
Eye Disease
Interventions
Drug: trans-resveratrol
First Posted Date
2014-12-22
Last Posted Date
2014-12-22
Lead Sponsor
Huazhong University of Science and Technology
Target Recruit Count
20
Registration Number
NCT02321176
Locations
🇨🇳

Tongji Medical College of HUST, Wuhan, Hubei, China

Effects of High-Dose Resveratrol in Non-Diabetic Obese Males

Phase 2
Completed
Conditions
Diabetes
Obesity
Interventions
Drug: Placebo
Drug: Resveratrol
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Khoo Teck Puat Hospital
Target Recruit Count
36
Registration Number
NCT02247596
Locations
🇸🇬

Khoo Teck Puat Hospital, Singapore, Singapore

RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)

Not Applicable
Completed
Conditions
Peripheral Arterial Disease
Interventions
Drug: Placebo
Drug: Resveratrol
First Posted Date
2014-09-23
Last Posted Date
2018-04-30
Lead Sponsor
Northwestern University
Target Recruit Count
66
Registration Number
NCT02246660
Locations
🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Phase 2
Completed
Conditions
Metabolic Syndrome X
Interventions
Drug: Placebo
Drug: Resveratrol
First Posted Date
2014-04-15
Last Posted Date
2020-09-17
Lead Sponsor
University of Guadalajara
Target Recruit Count
24
Registration Number
NCT02114892
Locations
🇲🇽

Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Drug: resveratrol
First Posted Date
2014-02-13
Last Posted Date
2015-12-08
Lead Sponsor
Federal University of Rio Grande do Sul
Target Recruit Count
19
Registration Number
NCT02062190
Locations
🇧🇷

HCPA, Porto Alegre, RS, Brazil

Influence of Caloric Restriction and Resveratrol in the Sirtuin System in Women and Men Aged 55 to 65 Years

First Posted Date
2012-08-20
Last Posted Date
2016-04-18
Lead Sponsor
InCor Heart Institute
Target Recruit Count
48
Registration Number
NCT01668836
Locations
🇧🇷

INCOR - Heart Institute, São Paulo, Brazil

Resveratrol Supplementation on Exercise in Healthy Sedentary Adults

Phase 2
Completed
Conditions
Sedentary Lifestyle
Interventions
Drug: placebo
Drug: Resveratrol
First Posted Date
2012-06-08
Last Posted Date
2014-06-23
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
13
Registration Number
NCT01615445
Locations
🇨🇦

The Ottawa Hospital -General Campus, Ottawa, Ontario, Canada

Resveratrol for Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
Drug: Resveratrol
First Posted Date
2012-01-06
Last Posted Date
2016-06-14
Lead Sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Target Recruit Count
119
Registration Number
NCT01504854
Locations
🇺🇸

Howard University, Washington, District of Columbia, United States

🇺🇸

Mayo Clinic, Jacksonville, Jacksonville, Florida, United States

🇺🇸

Mount Sinai School of Medicine, New York, New York, United States

and more 23 locations

Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol

Phase 2
Completed
Conditions
Dyslipidaemia
Insulin Resistance
Interventions
Drug: Resveratrol
First Posted Date
2011-10-14
Last Posted Date
2014-05-06
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
8
Registration Number
NCT01451918
Locations
🇨🇦

Toronto General Hospital, Toronto, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy